DexCom earnings beat by $0.03, revenue topped estimates
On Tuesday, Jefferies analyst Brandon Couillard adjusted the price target for Danaher Corporation (NYSE:DHR) shares to $230 from the previous $260 while retaining a Buy rating on the stock. The new target sits within the broader analyst range of $205-$310, with the consensus remaining strongly bullish at 1.44 (Strong Buy). Couillard’s analysis acknowledged the company’s performance, noting that the expectations were met, primarily due to the influence of flu season, and highlighted the positive trends in bioprocessing, which exceeded expectations and provided a boost to the company’s credibility after a challenging fourth quarter. According to InvestingPro data, Danaher currently appears fairly valued, with a market capitalization of $138.73 billion.
The analyst pointed out that the earnings per share (EPS) guidance of $7.60 to $7.75 for Danaher includes some room for unforeseen challenges, citing the first quarter’s earnings beat, cost-saving measures, and favorable foreign exchange conditions as factors contributing to this cushion. With current diluted EPS at $5.29 and a P/E ratio of 36.49, the stock trades at a premium multiple. Couillard suggested that a more optimistic scenario could see the EPS reaching approximately $8 in 2025 and potentially $9 in 2026. InvestingPro subscribers can access 12 additional exclusive tips about Danaher’s financial health and market position.
In his comments, Couillard expressed confidence in the company’s long-range plan (LRP), indicating that management has maintained its commitment to this strategy. Despite acknowledging the current sentiment and macroeconomic challenges, the Jefferies analyst believes that Danaher’s stock has the potential to progressively increase in value. Additionally, he mentioned the possibility of mergers and acquisitions (M&A) as an opportunity for the company to further enhance its market position and drive shareholder value.
Danaher Corporation, known for its diversified portfolio in science and technology, has been navigating a complex market environment. The company’s recent performance in bioprocessing and its strategic initiatives, as noted by Jefferies, suggest a path to growth despite broader economic pressures. The revised price target reflects a balance between recent achievements and cautious optimism for the company’s future financial health.
In other recent news, Danaher Corporation reported its first-quarter 2025 earnings, surpassing analysts’ expectations with an adjusted earnings per share (EPS) of $1.88, compared to the forecasted $1.62. The company also exceeded revenue projections, reporting $5.74 billion against the anticipated $5.56 billion. Despite core revenue remaining flat year-over-year, Danaher experienced significant growth in its recurring revenue segments. The company is targeting $150 million in cost savings through restructuring efforts, amid challenges like a high single-digit decline in the China market due to changes in diagnostic procurement. Analysts from firms like Bank of America and Jefferies have noted Danaher’s strategic positioning and resilience in the market. Danaher projects core revenue growth of approximately 3% for the full year 2025, with adjusted EPS guidance ranging from $7.60 to $7.75. The company continues to focus on non-discretionary, regulated markets, which account for over 80% of its revenue.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.